Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial to Assess the Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT01379807 is registered in ClinicalTrials.gov with Grupo Gallego de Investigaciones Oncologicas as lead sponsor.

NCT NCT01379807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01379807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial to Assess the Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
Grupo Gallego de Investigaciones Oncologicas
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2010
Completion date
December 31, 2015
Enrollment
55 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma, gastroesophageal junction adenocarcinoma